Ghrelin-induced orexigenic effect in rats depends on the metabolic status and is counteracted by peripheral CB1 receptor antagonism

PLoS One. 2013;8(4):e60918. doi: 10.1371/journal.pone.0060918. Epub 2013 Apr 2.

Abstract

Ghrelin is an endogenous regulator of energy homeostasis synthesized by the stomach to stimulate appetite and positive energy balance. Similarly, the endocannabinoid system is part of our internal machinery controlling food intake and energy expenditure. Both peripheral and central mechanisms regulate CB1-mediated control of food intake and a functional relationship between hypothalamic ghrelin and cannabinoid CB1 receptor has been proposed. First of all, we investigated brain ghrelin actions on food intake in rats with different metabolic status (negative or equilibrate energy balance). Secondly, we tested a sub-anxiogenic ultra-low dose of the CB1 antagonist SR141716A (Rimonabant) and the peripheral-acting CB1 antagonist LH-21 on ghrelin orexigenic actions. We found that: 1) central administration of ghrelin promotes food intake in free feeding animals but not in 24 h food-deprived or chronically food-restricted animals; 2) an ultra-low dose of SR141716A (a subthreshold dose 75 folds lower than the EC50 for induction of anxiety) completely counteracts the orexigenic actions of central ghrelin in free feeding animals; 3) the peripheral-restricted CB1 antagonist LH-21 blocks ghrelin-induced hyperphagia in free feeding animals. Our study highlights the importance of the animaĺs metabolic status for the effectiveness of ghrelin in promoting feeding, and suggests that the peripheral endocannabinoid system may interact with ghrelińs signal in the control of food intake under equilibrate energy balance conditions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Eating / drug effects
  • Ghrelin / pharmacology*
  • Male
  • Piperidines / pharmacology
  • Pyrazoles / pharmacology
  • Rats
  • Rats, Wistar
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors*
  • Receptor, Cannabinoid, CB1 / metabolism*
  • Rimonabant
  • Triazoles / pharmacology

Substances

  • 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole
  • Ghrelin
  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Triazoles
  • Rimonabant

Grants and funding

The present work has been supported by grants from the European Union 7th Framework Programme (Health-F2-2008-223713, REPROBESITY); the following grants from the Spanish Ministry of Science and Innovation: fundamental research project (SAF2010-20521), National Institute of Health National Institute of Health ‘CarlosIII’ (PI07/1226), Red de Trastornos Adictivos EU-ERDF (RD06/0001/0000), and CIBERobn EU-ERDF(CB06/03/1008); grant EU-ERDF PAIDI CTS-433 and grant PI45403 from the Andalusian Ministry of Economy, Science and Innovation; grant PR 28/11-18295 from Spanish Ministry of Education and grant from the Fundación Eugenio Rodríguez Pascual. MTRL is a recipient of a FPU fellowship from the Spanish Ministry of Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.